Many decisions made in early biopharmaceutical development have a significant impact on the quality of the final product. Often, quality issues are thought to be applicable only to cGMP activities, when in fact quality considerations should be involved in all stages of product development, including cell line development, upstream and downstream development. Dr. Sheila Magil, Senior Consultant, will be discussing some of the key quality decisions necessary in early biopharmaceutical development and demonstrating how they affect overall development programs as part of Pfenex Strain Engineering’s Strategies for Accelerating Preclinical Development of Vaccines and Therapeutic Proteins seminar to be held on Tuesday, August 20, 2013 from 1:00-5:00PM at the Westin Boston Waterfront hotel. Joining Dr. Magil on the program will be thought leaders Mark Poznansky, MD, PhD, Director of the Vaccine & Immunotherapy Center at Massachusetts General Hospital, Kevin P. Killeen, PhD, Chief Scientific Officer, Matrivax Research and Development Corporation, and Dominic Esposito, Ph.D. Director, Protein Expression Laboratory Advanced Technology Program at SAIC-Frederick, Inc. If you’re facing quality challenges, meet Sheila for a cocktail at the reception sponsored by SAFC at 5:00PM to learn how BPTC can help you de-risk your program.